Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Kenneth I Zheng¹, Feng Gao², Xiao-Bo Wang³, Qing-Feng Sun⁴, Ke-Hua Pan⁵, Ting-Yao Wang⁶, Hong-Lei Ma¹, Yong-Ping Chen¹, Wen-Yue Liu⁷, Jacob George⁸, Ming-Hua Zheng⁹

Affiliations

¹ MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
² Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
³ Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China.
⁴ Department of Infectious Diseases, Ruian People's Hospital, Wenzhou, China.
⁵ Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁶ Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁷ Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁸ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia. Electronic address: jacob.george@sydney.edu.au.
⁹ MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Institute of Hepatology, Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China. Electronic address: zhengmh@wmu.edu.cn.

PMID: 32320741
PMCID: PMC7166301
DOI: 10.1016/j.metabol.2020.154244

Multicenter Study

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Kenneth I Zheng et al. Metabolism. 2020 Jul.

. 2020 Jul:108:154244.

doi: 10.1016/j.metabol.2020.154244. Epub 2020 Apr 19.

Authors

Kenneth I Zheng¹, Feng Gao², Xiao-Bo Wang³, Qing-Feng Sun⁴, Ke-Hua Pan⁵, Ting-Yao Wang⁶, Hong-Lei Ma¹, Yong-Ping Chen¹, Wen-Yue Liu⁷, Jacob George⁸, Ming-Hua Zheng⁹

Affiliations

¹ MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
² Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
³ Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China.
⁴ Department of Infectious Diseases, Ruian People's Hospital, Wenzhou, China.
⁵ Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁶ Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁷ Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁸ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia. Electronic address: jacob.george@sydney.edu.au.
⁹ MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Institute of Hepatology, Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China. Electronic address: zhengmh@wmu.edu.cn.

PMID: 32320741
PMCID: PMC7166301
DOI: 10.1016/j.metabol.2020.154244

No abstract available

Keywords: COVID-19; MAFLD; Obesity; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All authors declare no conflict of interests.

Comment in

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
Hussain A, Vasas P, El-Hasani S. Hussain A, et al. Metabolism. 2020 Jul;108:154256. doi: 10.1016/j.metabol.2020.154256. Epub 2020 Apr 29. Metabolism. 2020. PMID: 32360211 Free PMC article. No abstract available.

References

1. WHO characterizes COVID-19 as a pandemic. March 13, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-a...
1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. In press. - DOI - PMC - PubMed
1. Eslam M., Newsome P.N., Anstee Q.M., Targher G., Gomez M.R., Zelber-Sagi S., et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020 doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
1. Arias-Loste M.T., Fábrega E., López-Hoyos M., Crespo J. The crosstalk between hypoxia and innate immunity in the development of obesity-related nonalcoholic fatty liver disease. Biomed Res Int. 2015;2015:319745. - PMC - PubMed
1. Lee C.H., Choi S.H., Chung G.E., Park B., Kwak M.S. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int. 2018;38:2091–2100. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Affiliations

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Authors

Affiliations

Conflict of interest statement

Comment in

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous